Chase Schwalbach

Chase joined FidoCure as Chief Product Officer in 2022. He brings with him extensive experience in Genomics, Engineering, and Data Science. His passions are to bring together all the technical pieces of the puzzle to help move the world forward, helping animals and humans.

Prior to joining FidoCure, Chase spent over 5 years at Tempus Labs, joining as employee 90 and playing instrumental roles in Engineering, Data Science, Operations, and Science R&D while the company scaled to >2,000 employees. Chase’s role for the first 3 years was to scale the core business via both automation and launching new tests (moving from the first outsourced tissue panel to an in-house tissue test, along with the first liquid test). He moved on from there to launch Tempus’ algorithmic diagnostic business and led the launch of their HRD (Homologous Recombination Deficiency) and TO (Tumor of Unknown Origin) tests. For the last 1.5 years, Chase led the R&D Product and Strategy for the company. His main focus was leading strategic efforts in liquid biopsies and future assays.